These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
    Author: Simonsson B, Oberg G, Björeman M, Björkholm M, Carneskog J, Gahrton G, Hast R, Karl H, Lanng-Nielsen J, Löfvenberg E, Malm C, Turesson I, Udén AM, Vilén L, Weis-Bjerrum O.
    Journal: Bone Marrow Transplant; 1996 May; 17 Suppl 3():S63-4. PubMed ID: 8769705.
    Abstract:
    With the rationale that a significant reduction of the malignant clone in CML might prolong time to metamorphosis, intensive treatment was given to patients < or = 55 years. Six months of hydroxyurea and high dose interferon-alpha (IFN-alpha) was followed by one to three courses of intensive chemotherapy. Patients who had a donor were allotransplanted and patients who became Ph-negative in bone marrow were autotransplanted. On 1 May 1995, 160 patients were registered in the study. Fifty-one percent of the patients who received six months IFN-alpha and hydroxyurea had a significant Ph-reduction and 5% became Ph-negative. The corresponding figures after two intensive chemotherapy courses were 47 and 28%, respectively. Twenty-seven of 30 autotransplanted patients have been analysed for Ph. Seventeen have relapsed cytogenetically, while ten are Ph-negative 1-64 + months after ABMT. BMT was performed in 59 patients. The actuarial 6-year survival from diagnosis of all 160 registered patients is 68%, which seems to be better than for age-matched historical controls.
    [Abstract] [Full Text] [Related] [New Search]